Literature DB >> 10163442

Healthcare reform in Europe.

P Belien1.   

Abstract

The European welfare states are currently struggling with tremendous budget problems. Most debate appears to be concerned with how to cut healthcare costs. Unfortunately, limiting the state's costs, rather than enhancing the people's well-being, has become the prime focus of new healthcare strategies in the European welfare states. The result has been a reduction in the quality and availability of healthcare services and a diminishing contribution to medical innovation by most European countries. Abandonment of the 'pay-as-you-go' financing system is the only solution to increasingly unsustainable welfare state healthcare systems. A system financed by a capitalisation mechanism would be protected from the increasing costs associated with demographic evolution, while providing all members of society with the opportunity for affordable healthcare coverage.

Entities:  

Mesh:

Year:  1996        PMID: 10163442     DOI: 10.2165/00019053-199600102-00015

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  3 in total

Review 1.  Consequences of implementing a drug budget for office-based physicians in Germany.

Authors:  O Schöffski
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

2.  The impact of recent legislative change in Germany.

Authors:  F E Münnich; K Sullivan
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

3.  Physicians' perspectives on caring for patients in the United States, Canada, and West Germany.

Authors:  R J Blendon; K Donelan; R Leitman; A Epstein; J C Cantor; A B Cohen; I Morrison; T Moloney; C Koeck; S W Levitt
Journal:  N Engl J Med       Date:  1993-04-08       Impact factor: 91.245

  3 in total
  3 in total

1.  The emergence of managed care in Europe. Some thoughts on the politics of healthcare reform.

Authors:  C Elze
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

Review 2.  Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes.

Authors:  Lisa L Ioannides-Demos; Joseph E Ibrahim; John J McNeil
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

3.  Analysis of yearly variations in drug expenditure for one patient using data warehouse in a hospital.

Authors:  Yufeng Chen; Yasushi Matsumura; Katsuhiko Nakagawa; Shanmei Ji; Hirohiko Nakano; Tadamasa Teratani; Qiyan Zhang; Takahiro Mineno; Hiroshi Takeda
Journal:  J Med Syst       Date:  2007-02       Impact factor: 4.460

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.